Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeted therapy

Dabrafenib–trametinib is effective in paediatric high-grade glioma

Nature Reviews Clinical Oncology volume 20, page 734 (2023)Cite this article

Subjects

Children with recurrent high-grade glioma typically receive combination chemotherapy, although these regimens provide limited benefit and are highly toxic. Approximately 5–10% of these patients have BRAFV600E-mutant tumours. Now, data from a phase II trial demonstrate the efficacy of the BRAF inhibitor dabrafenib combined with the MEK inhibitor trametinib in this patient subset.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Dabrafenib–trametinib is effective in paediatric high-grade glioma. Nat Rev Clin Oncol 20, 734 (2023). https://doi.org/10.1038/s41571-023-00820-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00820-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer